Difference between revisions of "Team:ASIJ Tokyo"

Line 1: Line 1:
 
{{ASIJ_Tokyo/CSS}}
 
{{ASIJ_Tokyo/CSS}}
 
{{:Team:ASIJ_Tokyo/bar}}
 
{{:Team:ASIJ_Tokyo/bar}}
−
 
  
 
<html>
 
<html>
Line 31: Line 30:
 
}
 
}
  
 +
footer {
 +
border-top: 2px dotted #fff;
 +
margin-top: 10%;
 +
}
 +
 +
#footer_logo {
 +
height: 130px;
 +
display: block;
 +
margin: 25px;
 +
margin-left: auto;
 +
margin-right: auto;
 +
}
 +
 +
footer p{
 +
float: right;
 +
color: #88C1EF;
 +
}
 +
 +
footer p a{
 +
color: #88C1EF;
 +
}
  
 
    
 
    
Line 129: Line 149:
 
<p> Alpha-1 Antitrypsin deficiency is a common genetic disorder -- the defective gene for which is carried by 1 in 25 people -- which arises from a single base pair mutation in the SERPINA1 gene, resulting in the production of a form of antitrypsin prone to polymerization. The mutated antitrypsin then builds up in liver cells and is unable to inhibit proteases in the lungs, leading to damage in both. Using CRISPR-Cas9 technology, we aimed to fix the error in SERPINA1 so that proper antitrypsin can be produced. We will show proof of concept in E. Coli cells using osmy secretion tags and GFP as a reporter. We hope to design a liver organ bud using IPS cell technology to deliver function A1AT through collaboration with Dr. Kagimoto of Healios Japan KK.
 
<p> Alpha-1 Antitrypsin deficiency is a common genetic disorder -- the defective gene for which is carried by 1 in 25 people -- which arises from a single base pair mutation in the SERPINA1 gene, resulting in the production of a form of antitrypsin prone to polymerization. The mutated antitrypsin then builds up in liver cells and is unable to inhibit proteases in the lungs, leading to damage in both. Using CRISPR-Cas9 technology, we aimed to fix the error in SERPINA1 so that proper antitrypsin can be produced. We will show proof of concept in E. Coli cells using osmy secretion tags and GFP as a reporter. We hope to design a liver organ bud using IPS cell technology to deliver function A1AT through collaboration with Dr. Kagimoto of Healios Japan KK.
 
</div>
 
</div>
 +
 +
        <footer>
 +
  <img id=footer_logo src="https://static.igem.org/mediawiki/2018/4/4b/T--ASIJ_Tokyo--TeamLogo.png" alt="iGEMlogo">
 +
<h6>Icon used in the background made by <a href="https://www.flaticon.com/authors/ddara">dDara</a>from <a href="www.flaticon.com">www.flaticon.com</a></h6>
 +
        </footer>
  
 
</div>
 
</div>
Line 135: Line 160:
  
 
</html>
 
</html>
−
 
−
{{ASIJ_Tokyo/footer}}
 

Revision as of 08:18, 14 October 2018

liver

A1-AT
deLIVERy

Using Stem Cell and CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency

ABSTRACT

Alpha-1 Antitrypsin deficiency is a common genetic disorder -- the defective gene for which is carried by 1 in 25 people -- which arises from a single base pair mutation in the SERPINA1 gene, resulting in the production of a form of antitrypsin prone to polymerization. The mutated antitrypsin then builds up in liver cells and is unable to inhibit proteases in the lungs, leading to damage in both. Using CRISPR-Cas9 technology, we aimed to fix the error in SERPINA1 so that proper antitrypsin can be produced. We will show proof of concept in E. Coli cells using osmy secretion tags and GFP as a reporter. We hope to design a liver organ bud using IPS cell technology to deliver function A1AT through collaboration with Dr. Kagimoto of Healios Japan KK.